Valuation: Stereotaxis, Inc.

Market Cap 129M 111M 105M 95.58M 179M 12.35B 180M 1.25B 482M 6.28B 485M 475M 19.85B P/E 2026 *
-6.34x
P/E 2027 * -8.8x
Enterprise Value 129M 111M 105M 95.58M 179M 12.35B 180M 1.25B 482M 6.28B 485M 475M 19.85B EV / Sales 2026 *
3.76x
EV / Sales 2027 * 2.83x
Free-Float
78.85%
Yield 2026 *
-
Yield 2027 * -
1 day+2.71%
1 week+1.54%
Current month-8.33%
1 month-4.35%
3 months-28.26%
6 months-30.89%
Current year-42.61%
1 week 1.26
Extreme 1.265
1.4
1 month 1.26
Extreme 1.265
1.51
Current year 1.24
Extreme 1.24
2.86
1 year 1.24
Extreme 1.24
3.59
3 years 1.24
Extreme 1.24
3.59
5 years 1.24
Extreme 1.24
7.22
10 years 0.47
Extreme 0.47
10.3
Manager TitleAgeSince
Chief Executive Officer - 03/02/2017
Director of Finance/CFO 57 01/10/2019
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 79 01/02/2005
Chairman - 03/02/2017
Director/Board Member 71 29/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
1/7/26 Free

Director

43,103 0.0441%
1/7/26 Free

Director

43,103 0.0441%
1/7/26
DAFNA Capital Management LLC
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
+2.71%+1.54%-53.19%-20.00% 129M
-0.48%+0.70%+27.99%+17.77% 225B
-0.26%-2.63%+5.99%-21.17% 141B
+1.01%+6.72%-13.90%+23.03% 130B
+3.86%-0.70%-55.28%-15.60% 62.29B
+2.31%+1.22%-18.24%-13.71% 49.39B
+1.33%-1.29%+12.56%+15.65% 48.63B
-1.50%-1.17%+15.52%+26.33% 41.42B
-1.17%+0.27%+35.09%+48.52% 40.12B
+1.44%+0.45%-18.12%+50.39% 31.23B
Average +0.90%-3.63%-6.16%+11.12% 76.98B
Weighted average by Cap. +0.42%-2.40%+4.01%+10.07%

Financials

2026 *2027 *
Net sales 34.33M 29.58M 28.01M 25.39M 47.63M 3.28B 47.87M 333M 128M 1.67B 129M 126M 5.27B 45.67M 39.35M 37.26M 33.77M 63.35M 4.36B 63.67M 442M 170M 2.22B 172M 168M 7.01B
Net income -20.13M -17.35M -16.43M -14.89M -27.93M -1.92B -28.07M -195M -75.02M -979M -75.61M -73.95M -3.09B -14.77M -12.72M -12.05M -10.92M -20.49M -1.41B -20.59M -143M -55.02M -718M -55.46M -54.24M -2.27B
Net Debt - -
Logo Stereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters.
Employees
131
Date Price Change Volume
15/09/26 USD 1.320 +2.33% 682,851
11/09/26 USD 1.290 -0.77% 527,797
10/09/26 USD 1.300 -1.52% 625,835
09/09/26 USD 1.320 +1.54% 587,314
08/09/26 USD 1.300 -6.47% 727,251
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.290USD
Average target price
3.000USD
Spread / Average Target
+132.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STXS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!